Milan (IT) Central Division- Section
41 cases · page 2 of 2
Showing 31–40ALIUD PHARMA GmbH v.Respondent
1 Milan - Central Division - First Instance - central division UPC_CFI_698/2024 Order of the Court of First Instance of the Unified Patent Court delivered on 10/04/2025 APPLICANT/S 1) ALIUD PHARMA GmbH (Applicant) - Gottlieb-Daimler-Str. 19 - 89150 - Laichingen - DE Represented b
ZENTIVA K.S., ZENTIVA PORTUGAL, LDA v.Respondent
(ROP 313) 1) Parallelism between two cases or the allegation that the outcome of a judgment has a direct impact on another does not establish a legal interest to intervention pursuant to RoP 313. 2) The expression 'made in support, in whole or in part, of a claim, order or relief sought by one of the parties' in Rule 313.2 RoP must be interpreted as meaning that the intervening party's remedies must be non-contradictory to those of the party who has been supported, and therefore in accor
SharkNinja Italy S.R.L. v.Respondent
SharkNinja Italy S.R.L. filed a revocation action against Dyson Technology Limited's European Patent EP 2043492 before the Central Division Milan. The parties subsequently reached a settlement agreement and signed a term sheet, prompting the claimant to request withdrawal of the revocation action and closure of proceedings. The court allowed the withdrawal, declared the proceedings closed, and ordered reimbursement of 60% of the court fees (EUR 12,000) to the claimant.
Insulet Corporation v.Respondent
The costs of a preliminary injunction must be settled at the same time as the decision on the merits, since the outcome of the preliminary phase must be considered in the framework of the overall settlement of litigation costs; cost compensation cannot be parcelled out according to the outcome of the various stages of the case but must relate to the final decision on the case as a whole. The outcome of the preliminary phase concerning the application for a preliminary injunction, therefore,
EOFLOW Co., Ltd. v.Respondent
The costs of a preliminary injunction must be settled at the same time as the decision on the merits, since the outcome of the preliminary phase must be considered in the framework of the overall settlement of litigation costs; cost compensation cannot be parcelled out according to the outcome of the various stages of the case but must relate to the final decision on the case as a whole. The outcome of the preliminary phase concerning the application for a preliminary injunction, therefore,
STADAPHARM GmbH v.ACCORD HEALTHCARE B.V., ACCORD HEALTHCARE S.L.U., ACCORD HEALTHCARE LIMITED, Novartis AG
This is a preliminary order concerning an application by STADAPHARM GmbH under Rule 261.1(b) RoP seeking access to written pleadings and evidence filed in main proceedings (UPC_CFI_698/2024) pending before the Milan Central Division. The main proceedings involve a declaratory non-infringement action brought by three Accord Healthcare Group companies against Novartis AG regarding Novartis's patent EP2501384 (relating to Nilotinib). STADAPHARM claimed a specific interest in accessing the documents because Novartis had obtained a preliminary injunction against STADAPHARM before the Munich Regional Court based on the same patent. The order addresses procedural questions regarding the scope of Rule 262.1(b) access applications, the lodging of non-digitally signed submissions under Rule 4.1 RoP, and the hearing of parties under Rule 264 RoP.
Insulet Corporation v.Respondent
1) The intervener must proof an interest justifying the support to the reasons of one of the
Pfizer Manufacturing Belgium S.A, Pfizer Inc, Pfizer Europe MA EEIG, Pfizer S.A, Pfizer Ltd, Pfizer Pharma GmbH, Pfizer Service Company S.R.L., Pfizer B.V. v.GlaxoSmithKline Biologicals S.A.
1 Milan - Central Division - First Instance - central division UPC_CFI_476/2024 Procedural Order of the Court of First Instance of the Unified Patent Court delivered on 02/12/2024 Date of receipt of Statement of revocation : Not provided GlaxoSmithKline Biologicals S.A. (Defendant)
Insulet Corporation v.EOFLOW Co., Ltd.
In the proceedings for provisional measures, the Applicant is required to provide cumulatively reasonable evidence to satisfy the Court with sufficient degree of certainty that: (i) the Applicant is entitled to initiate proceedings under Art. 47 UPCA; (ii) the patent is valid; (iii) its rights are being infringed or that such infringement is imminent (Rule 211.2 RoP). The auxiliary request to amend the patent pursuant to Rule 30.2 RoP is not admissible in the proceedings for provisional mea
EOFLOW Co., Ltd. v.Insulet Corporation
1 1 Milan - Central Division - First Instance - central division UPC_CFI_380/2024 Procedural Order of the Court of First Instance of the Unified Patent Court delivered on 01/10/2024 In the matter INSULET CORPORATION 100 Nagog Park, Acton, MA 01720, USA represented by its CEO Jim Holl
EOFLOW Co., Ltd. v.Respondent
1 Milan - Central Division – First Instance - central division UPC_CFI_380/2024 Procedural Order in a Review proceeding of the Court of First Instance of the Unified Patent Court delivered on 24/09/2024. APPLICANT/S in the REVIEW proceedings 1) EOFLOW Co., Ltd. 302Ho, HUMAX VILLAGE
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.